Skip to main content

Advertisement

Table 6 Reduction in mean WOMAC subscores in placebo, GC and UC-II groups over 180 days

From: Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Parameter reduction Day Placebo (n = 53) GC (n = 57) UC-II (n = 54) p value
      Overalla GC vs PBO UC-II vs PBOb UC-II vs GCc
WOMAC pain 7 3.21 ± 0.58 4.57 ± 0.54 3.88 ± 0.55 - - - -
30 6.61 ± 1.04 7.89 ± 1.00 9.18 ± 1.01 - - - -
60 8.17 ± 1.10 10.1 ± 1.07 12.7 ± 1.09 0.0149 - 0.011 -
90 11.2 ± 1.17 12.7 ± 1.14 16.4 ± 1.16 0.0063 - 0.0059 -
120 12.9 ± 1.28 15.6 ± 1.22 19.9 ± 1.26 0.0005 - 0.0004 0.040
150 15.0 ± 1.21 17.5 ± 1.16 21.5 ± 1.20 0.0007 - 0.0006 0.047
180 17.0 ± 1.25 19.2 ± 1.20 24.0 ± 1.23 0.0003 - 0.0003 0.016
WOMAC stiffness 7 3.47 ± 0.64 4.22 ± 0.61 4.24 ± 0.62 - - - -
30 6.81 ± 1.10 8.76 ± 1.05 9.28 ± 1.07 - - - -
60 9.36 ± 1.28 11.5 ± 1.25 13.1 ± 1.27 - - - -
90 11.3 ± 1.36 13.8 ± 1.32 17.0 ± 1.35 0.0158 - 0.010 -
120 13.6 ± 1.40 15.0 ± 1.34 20.0 ± 1.39 0.0035 - 0.0039 0.029
150 15.5 ± 1.32 17.7 ± 1.26 21.3 ± 1.31 0.0079 - 0.0058 -
180 17.8 ± 1.31 19.4 ± 1.27 23.8 ± 1.30 0.0043 - 0.004 0.044
WOMAC physical function 7 3.17 ± 0.56 4.14 ± 0.53 3.91 ± 0.53 - - - -
30 6.30 ± 1.00 7.80 ± 0.96 9.26 ± 0.98 - - - -
60 7.75 ± 1.08 9.50 ± 1.05 11.9 ± 1.07 0.0278 - 0.020 -
90 10.4 ± 1.17 12.1 ± 1.14 15.1 ± 1.16 0.0182 - 0.0136 -
120 12.7 ± 1.20 14.5 ± 1.15 17.9 ± 1.19 0.0083 - 0.0064 -
150 14.8 ± 1.19 16.9 ± 1.14 20.0 ± 1.18 0.0078 - 0.006 -
180 17.3 ± 1.21 18.8 ± 1.16 22.5 ± 1.20 0.0068 - 0.007 -
  1. Values presented as Mean ± SE
  2. aOverall p value was obtained by comparing the mean changes among the three groups using ANCOVA
  3. bSignificant difference between the UC-II and the placebo groups using Tukey-Kramer test
  4. cSignificant difference between the UC-II and the GC groups using Tukey-Kramer test. ‘-’denotes a non-significant statistical outcome